Treatment and management of autoimmune diseases focus on controlling symptoms, modulating the immune response, and addressing ...

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

It’s shocking to see the news that autoimmune conditions are skyrocketing. And 80 percent of cases are in women, according to ...

Simon Schrapel AM, Professor Anthony Williams, Professor Tom Gordon, Dr Brendan Nelson AO, Lauren Hillman, Catherine ...

Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...

The most comprehensive map of the developing human thymus sheds light on how immune responses are built and maintained at early life, with implications for understanding and treating immunodeficiency, ...

WILMINGTON, Del., November 18, 2024 -- ( BUSINESS WIRE )--Incyte (Nasdaq:INCY) today announced that it will pause enrollment ...

Large database study finds no increase in mortality, although other endpoints haven’t yet been reported, and the findings ...